Half-year report · Q2
9776.TEDINET S100ULLX
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥338m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥343m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥515m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥344m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥222m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥380m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥16.4bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥407m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥584m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥395m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥398m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥370m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥70.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥37m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥158m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥352m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥800m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥426m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥545m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所スタンダード市場札幌証券取引所 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)伊達アセットマネージメント合同会社 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)札幌市厚別区もみじ台南３丁目３番15号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社エスアールエル | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１丁目８－１ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)伊達 忠一 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)札幌市厚別区 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)永井 詳二 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)株式会社北海道銀行 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)札幌市中央区大通西４丁目１番地 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)株式会社北洋銀行 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)札幌市中央区大通西３丁目７番地 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)萬田 直紀 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)札幌市中央区 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |